EUROPEAN COMMISSION



HEALTH & CONSUMERS DIRECTORATE-GENERAL

Public Health and Risk Assessment **Risk assessment**

Scientific Committee on Consumer Safety

WG 'Methodologies' -21 February 2012

Minutes

1. WELCOME AND APOLOGIES

The Chairman of the Working Group welcomed the participants.

2. ADOPTION OF THE AGENDA

The draft agenda was adopted as proposed (see annex).

3. DECLARATION OF INTEREST ON MATTERS OF THE AGENDA No new declarations of interest were made

4. **RISK ASSESSMENT FOR INHALATION EXPOSURE**

A draft guideline document by a Cosmetics Europe task force on the risk assessment of cosmetic products with a possible inhalation exposure was presented and discussed.

5. SAFETY TESTING OF SUBSTANCES WITH LOW BIOAVAILABILITY

Following some recent inconclusive risk assessments on cosmetic ingredients with low bioavailability, Cosmetics Europe presented its view on this issue. It was agreed that further discussion is needed and a workshop maybe organised to collect expert input.

6. UPDATES TO NOG

INTESTINAL MODELS TO ASSESS ORAL BIOAVAILABILIT
A draft text for inclusion in the NoG was discussed.
BIOMONITORING
A draft text for inclusion in the NoG was discussed.

7. GUIDANCE FOR ANNEX I OF THE COSMETICS REGULATION

The document "Guidelines on Annex I to Regulation (EC) No 1223/2009 on the Cosmetic Product Safety Report" was presented by the Commission and feedback from SCCS was collected for finalisation of the document.

8. SCIENTIFIC COMMITTEE'S JOINT OPINION ON NEW CHALLENGES FOR RISK ASSESSMENT The draft opinion was discussed and feedback will be collected for consideration by the WG.

9. ANY OTHER BUSINESS

Annex



EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL

Health systems and products **Risk assessment**

Scientific Committee on Consumer Safety (SCCC)

WG on Methodologies

21 February 2012 – B232 08/120

Draft agenda

- 1. WELCOME AND APOLOGIES
- 2. Adoption of the agenda
- 3. DECLARATION OF INTEREST ON MATTERS ON THE AGENDA
- 4. RISK ASSESSMENT FOR INHALATION EXPOSURE
- 5. SAFETY TESTING OF SUBSTANCES WITH LOW BIOAVAILABILITY
- 6. UPDATES TO NOG

 a. Intestinal models to assess oral bioavailability
 b. Biomonitoring
- 7. GUIDANCE FOR ANNEX I OF THE COSMETICS REGULATION
- 8. Scientific Committee's Joint opinion on New Challenges for Risk Assessment
- 9. ANY OTHER BUSINESS